Ocuphire Pharma to Present at the Aegis Virtual Conference
FARMINGTON HILLS, Mich., May 03, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company…
0,514$
0,66%
Echtzeit-Aktienkurs IGC Pharma Inc.
Bid:
Ask:
Nachrichten zur IGC Pharma Inc. Aktie
Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris
FARMINGTON HILLS, Mich., April 01, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company…
IGC Pharma adds Terry Lierman to its Board of Directors By Investing.com
IGC Pharma adds Terry Lierman to its Board of Directors…
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update
FARMINGTON HILLS, Mich., March 08, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company…
FSD Pharma Signs Agreement With Ingenu CRO to Conduct a Clinical Trial To Determine the Safety and Efficacy Effects of its Proprietary Blend Beverage unbuzzd(TM)
FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets…
Ascendiant Capital starts IGC Pharma coverage with buy, sets $2.75 target on stock By Investing.com
Ascendiant Capital starts IGC Pharma coverage with buy, sets $2.75 target on stock…
IGC Pharma files for $100M mixed shelf
…
Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
FARMINGTON HILLS, Mich., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical…
Inozyme Pharma to Participate in Upcoming Investor Conferences
BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage…
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY)(“Company” or “Inozyme”), a clinical-stage rare disease…
Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
FARMINGTON HILLS, Mich., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical…
IGC Pharma files to sell up to 10M shares
…
Avalyn to Provide Keynote Presentation at the Formulation & Delivery U.S. 2023 Conference
SEATTLE, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of…
: Viatris and Ocuphire Pharma get FDA green light for eye treatment
Viatris Inc. VTRS and Ocuphire Pharma Inc. OCUP said Wednesday that the U.S. Food and Drug Administration has approved Ryzumvi…
Ocuphire Pharma to Participate in Three Upcoming Investment Bank Conferences
FARMINGTON HILLS, Mich., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical…
Form 8-K IGC Pharma, Inc. For: Aug 18
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 10-K IGC Pharma, Inc. For: Mar 31
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 8-K IGC Pharma, Inc. For: Jun 30
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
IGC Pharma secures $12M credit
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
IGC Raises $3M Via Private Placement With Asset Management Firm Bradbury
IGC Pharma, Inc. (AMEX: IGC) bagged a strategic investment read more...…
IGC Pharma announces $3M private placement of common stock
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
IGC Announces Rebranding, Changes Name to IGC Pharma, Inc.
POTOMAC, Md., March 20, 2023 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the…
IGC Q3 2023 Revenue Grows 133% YoY, What About Net Loss?
India Globalization Capital, Inc. (dba IGC, Inc.) (AMEX:IGC) released its third fiscal quarter 2023 financial results, revealing revenue of $332,000,…
India Globalization Capital GAAP EPS of -$0.04, revenue of $0.33M
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
IGC Reports Financial Results for Third Fiscal Quarter Ended Dec. 31, 2022
POTOMAC, Md., Feb. 14, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- India Globalization Capital, Inc. (dba IGC, Inc.)…
IGC to be Featured in Feb. 10 Radius Research Investor Webinar
POTOMAC, Md., Feb. 08, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- India Globalization Capital, Inc. (NYSE American: IGC)…
IGC Applauds Signing of Bipartisan Medical Marijuana and Cannabidiol Research Expansion Act
POTOMAC, Md., Dec. 07, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- India Globalization Capital, Inc (NYSE American: IGC)…
IGC to Present at the RHK 2022 Disruptive Growth Conference
POTOMAC, Md., Nov. 30, 2022 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc (NYSE American: IGC) (“IGC” or the…
India Globalization Capital GAAP EPS of -$0.05, revenue of $0.2M
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…